# Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

> **NCT00780416** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 189 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MP-424
- **DRUG:** Ribavirin
- **DRUG:** Peginterferon Alfa-2b
- **DRUG:** Ribavirin
- **DRUG:** Peginterferon Alfa-2b

## Key facts

- **NCT ID:** NCT00780416
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780416, "Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00780416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*